Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3A_____%2F23%3AN0000003" target="_blank" >RIV/60162694:_____/23:N0000003 - isvavai.cz</a>
Alternative codes found
RIV/61383082:_____/23:00001287 RIV/00216208:11110/23:10470920
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619853/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619853/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fimmu.2023.1271353" target="_blank" >10.3389/fimmu.2023.1271353</a>
Alternative languages
Result language
angličtina
Original language name
Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection
Original language description
Although vaccines against COVID-19 are effective tools in preventing severe disease, recent studies have shown enhanced protection after vaccine boosters. The aim of our study was to examine the dynamics and duration of both humoral and cellular immune responses following a three-dose regimen of the BNT162b2 mRNA vaccine. In a longitudinal prospective study we enrolled 86 adults who received the BNT162b2 vaccine, 35 unvaccinated individuals with a history of mild COVID-19 and a control group of 30 healthy SARS-CoV-2 seronegative persons. We assessed the SARS-CoV-2-specific T cell responses and IgG production up to 12 months post the third BNT162b2 dose in 24 subjects. The vaccinated group had significantly higher IgG antibody levels after two doses compared to the convalescent group (p<0.001). After the third dose, IgG levels surged beyond those detected after the second dose (p<0.001). Notably, these elevated IgG levels were maintained 12 months post the third dose. After two doses, specific T cell responses were detected in 87.5% of the vaccinated group. Additionally, there was a significant decrease before the third dose. However, post the third dose, specific T cell responses surged and remained stable up to the 12-month period. Our findings indicate that the BNT162b2 vaccine induces potent and enduring humoral and cellular responses, which are notably enhanced by the third dose and remain persistant without a significant decline a year after the booster. Further research is essential to understand the potential need for subsequent boosters.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
<a href="/en/project/VI04000078" target="_blank" >VI04000078: The development of a comprehensive assessment methodology for the immune preparedness of members of the security and protective services responding to the COVID-19 pandemic</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in immunology
ISSN
1664-3224
e-ISSN
1664-3224
Volume of the periodical
14
Issue of the periodical within the volume
17.10.2023
Country of publishing house
CH - SWITZERLAND
Number of pages
6
Pages from-to
nestrankovano
UT code for WoS article
001093015100001
EID of the result in the Scopus database
—